Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-eluting stents: some first-generation problems.

Bruce E Murphy1

  • 1Arkansas Heart Hospital, and University of Arkansas for Medical Sciences, 7 Shackleford West Boulevard, Little Rock, AR 72211-3714, USA. bruce.murphy@arheart.com

The American Heart Hospital Journal
|December 18, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of the Strong Hearts program at two years post program completion.

Journal of osteopathic medicine·2024
Same author

Effects of the Strong Hearts program after a major cardiovascular event in patients with cardiovascular disease.

Journal of osteopathic medicine·2023
Same author

The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert Panel.

JACC. Cardiovascular interventions·2017
Same author

Usefulness of optical coherent reflectometry with guided radiofrequency energy to treat chronic total occlusions in peripheral arteries (the GRIP trial).

The American journal of cardiology·2004
Same journal

Spontaneous coronary artery dissection presenting with stroke.

The American heart hospital journal·2014
Same journal

Acute Myocardial Infarction Secondary to Suspected Paradoxical Emboli through Patent Foramen Ovale in a Young Woman.

The American heart hospital journal·2014
Same journal

Life-threatening Takotsubo Cardiomyopathy.

The American heart hospital journal·2014
Same journal

Late-term Post-operative Recanalization of a Fistula between the Coronary Artery and Bronchial Vein.

The American heart hospital journal·2014
Same journal

A rare location and presentation of papillary fibroelastoma.

The American heart hospital journal·2014
Same journal

Acute pericarditis superimposed on right bundle branch block, posterior fascicular block, and interatrial block.

The American heart hospital journal·2014
See all related articles

The Cypher drug-eluting stent, initially anticipated, was removed from use due to serious complications like edge dissection and subacute thrombosis. This highlights the need for caution with new cardiovascular devices.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Medical Device Technology

Background:

  • Drug-eluting stents (DES) represent a significant advancement in treating coronary atherosclerosis.
  • The introduction of the Cypher Sirolimus-Eluting Coronary Stent (SES) generated considerable interest in cardiology.
  • Early adoption of novel medical devices requires careful evaluation of their real-world performance.

Observation:

  • The Arkansas Heart Hospital experienced significant issues with the Cypher SES within six months of its introduction.
  • Specific adverse events, including edge dissection and subacute thrombosis, were observed.
  • These complications led to the discontinuation of the Cypher SES at the institution.

Findings:

  • First-generation drug-eluting stents, such as the Cypher SES, may possess unforeseen limitations when used in routine clinical practice.

Related Experiment Videos

  • The observed adverse events necessitated the removal of the device from inventory.
  • The performance issues underscore the potential risks associated with new interventional cardiology technologies.

    • Implications:

    • New cardiovascular devices, despite initial enthusiasm, must be assessed rigorously for safety and efficacy.
    • The experience with the Cypher SES suggests a need for continued vigilance and research into DES technology.
    • Further development is required to create improved devices that offer more definitive treatment for coronary artery disease.